鶹ý

Feature Channels: Parkinson’s Disease

Filters close
Released: 21-Nov-2024 10:00 AM EST
Ochsner Health Selected as a Site for Global Parkinson's Disease Study Researching the Black and African American Population
Ochsner Health

Ochsner Health, a leading nonprofit healthcare provider in the Gulf South, has been selected by the Global Parkinson’s Genetics Program (GP2) as one of six new study sites for the Black and African American Connections to Parkinson’s Disease study.

鶹ý: Parkinson's Drug Changes the Gut Microbiome for the Worse Due to Iron Deficiency
Released: 21-Nov-2024 6:00 AM EST
Parkinson's Drug Changes the Gut Microbiome for the Worse Due to Iron Deficiency
University of Vienna

In a groundbreaking new study, conducted within the framework of the FWF-funded Cluster of Excellence "Microbiomes drive Planetary Health", scientists from the University of Vienna, in collaboration with the University of Southampton, Aalborg University and Boston University, have revealed that the widely prescribed Parkinson's disease drug entacapone significantly disrupts the human gut microbiome by inducing iron deficiency. The study, published in Nature Microbiology, provides new insights into the often-overlooked impact of human-targeted drugs on the microbial communities that play a critical role in human health.

鶹ý: AI Speaks Volumes When It Comes to Detecting Parkinson's Disease
Released: 20-Nov-2024 8:20 PM EST
AI Speaks Volumes When It Comes to Detecting Parkinson's Disease
University of South Australia

Algorithms that can detect subtle changes in a person’s voice are emerging as a potential new diagnostic tool for Parkinson’s disease, according to researchers from Iraq and Australia.

   
鶹ý: Out-of-Pocket Costs Continue to Rise for Neurologic Medications
Released: 31-Oct-2024 12:45 PM EDT
Out-of-Pocket Costs Continue to Rise for Neurologic Medications
Ohio State University Wexner Medical Center

Out-of-pocket costs continue to increase for patients who must buy commonly prescribed drugs to treat these five neurological diseases – epilepsy, multiple sclerosis (MS), peripheral neuropathy, Alzheimer’s disease and Parkinson’s disease. This is according to research published online in Neurology®, the medical journal of the American Academy of Neurology.

24-Oct-2024 4:05 PM EDT
Costs Still on the Rise for Drugs for Neurological Diseases
American Academy of Neurology (AAN)

The amount of money people pay out-of-pocket for branded drugs to treat neurological diseases like multiple sclerosis (MS), Alzheimer’s, and Parkinson’s disease continues to rise, especially for MS drugs, according to a study published in the October 30, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Released: 23-Oct-2024 12:15 PM EDT
Antibiotics and Antifungals May Slightly Affect Parkinson's Risk, Study Finds
Rutgers University-New Brunswick

New research by Rutgers Health researchers highlights a complex relationship between bacteria in the digestive tract and brain health.

Released: 18-Oct-2024 10:55 AM EDT
Speech Accessibility Project expands to Canada
Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign

The Speech Accessibility Project is now recruiting Canadian adults with Parkinson’s disease, cerebral palsy, amyotrophic lateral sclerosis, Down syndrome and those who have had a stroke.

鶹ý: Protein Shakeup: Researchers Uncover New Function of a Protein That May Unlock Age-Related Illnesses
Released: 17-Oct-2024 8:35 PM EDT
Protein Shakeup: Researchers Uncover New Function of a Protein That May Unlock Age-Related Illnesses
McMaster University

McMaster University researchers have discovered a previously unknown cell-protecting function of a protein, which could open new avenues for treating age-related diseases and lead to healthier aging overall.

鶹ý: 2012-P03731_CG-4D_IMAGINE.jpg?itok=k9SkLhtR
Released: 16-Oct-2024 3:45 PM EDT
High Flux Isotope Reactor a Fit for Nobel Laureate’s Designer Proteins
Oak Ridge National Laboratory

Biochemist David Baker — just announced as a recipient of the Nobel Prize for Chemistry — turned to the High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory for information he couldn’t get anywhere else. HFIR is the strongest reactor-based neutron source in the United States.

鶹ý: 1920_csacceletors-2024-demo-day-hlth.jpeg?10000
Released: 16-Oct-2024 12:30 PM EDT
HLTH 2024: Cedars-Sinai Accelerator Hosts Demo Day
Cedars-Sinai

Participants from the Cedars-Sinai Accelerator’s 10th class are set to showcase their leading-edge healthcare solutions during Demo Day at HLTH 2024 on Tuesday, Oct. 22, from 2:30 p.m. to 4 p.m. at The Venetian Expo Center in Las Vegas, Nevada.

鶹ý:Video Embedded challenging-current-understanding-study-reveals-rapid-release-of-dopamine-not-needed-for-initiating-movement
VIDEO
15-Oct-2024 7:30 PM EDT
Challenging Current Understanding, Study Reveals Rapid Release of Dopamine Not Needed for Initiating Movement
Harvard Medical School

At a glance: Study in mice reveals rapid release of dopamine is not needed for initiating movement but is important for activities related to reward-seeking and motivation. The findings help explain why the widely used Parkinson’s drug levodopa improves movement-related symptoms but often fails to ameliorate some cognitive ones. The work may inform the development of new therapies that restore both slow and fast dopamine action to treat multiple symptoms.

Released: 15-Oct-2024 11:25 AM EDT
Researchers Create ‘Mini Brains’ to Model Lewy Body Dementia and Pinpoint Treatments
Mayo Clinic

Lewy body dementia (LBD) is a progressive neurodegenerative disease that shares traits with both Parkinson's disease and Alzheimer's disease but can be more difficult to diagnose. Symptoms can include hallucinations, movement disorders, cognitive issues, sleep problems and depression.

Released: 14-Oct-2024 2:15 PM EDT
الباحثون يبتكرون “أدمغة مصغرة” لنمذجة خرف أجسام ليوي وتحديد العلاجات المناسبة
Mayo Clinic

خرف أجسام ليوي هو مرض تنكسي عصبي متفاقم يشترك في بعض سماته مع داء باركينسون و داء الزهايمر، ولكنه قد يكون أكثر صعوبة في التشخيص. يمكن أن تشمل الأعراض الهلوسات واضطرابات الحركة ومشاكل في الإدراك واضطرابات النوم والاكتئاب.

Released: 14-Oct-2024 1:55 PM EDT
Pesquisadores criam “minicérebros” para modelar a demência por corpos de Lewy e identificar tratamentos
Mayo Clinic

A demência por corpos de Lewy (DCL) é uma doença neurodegenerativa progressiva que compartilha características tanto da doença de Parkinson quanto da doença de Alzheimer, mas que pode ser mais difícil de ser diagnosticada. Os sintomas podem incluir alucinações, distúrbios do movimento, problemas cognitivos, problemas de sono e depressão.

Released: 14-Oct-2024 1:50 PM EDT
Investigadores Crean “Minicerebros” Para Modelar La Demencia Con Cuerpos De Lewy E Identificar Tratamientos
Mayo Clinic

La demencia con cuerpos de Lewy (DCL) es una enfermedad neurodegenerativa progresiva que comparte características tanto de la enfermedad de Parkinson cuanto de la enfermedad de Alzheimer, pero que puede ser más difícil de diagnosticar. Los síntomas pueden incluir alucinaciones, trastornos del movimiento, problemas cognitivos, problemas para dormir y depresión.

Released: 4-Oct-2024 1:05 PM EDT
UC Irvine researchers are first to reveal role of ophthalmic acid in motor function control
University of California, Irvine

A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target for Parkinson’s and other movement diseases.

鶹ý: Department of Defense-Funded Research May Lead to Breakthroughs for Parkinson's Symptom Management
Released: 4-Oct-2024 10:05 AM EDT
Department of Defense-Funded Research May Lead to Breakthroughs for Parkinson's Symptom Management
Binghamton University, State University of New York

Binghamton University, State University of New York Psychology Professor Christopher R. Bishop is part of a collaborative research team that recently received a four-year grant from The Department of Defense to investigate the underlying cause of neuropsychiatric symptoms in Parkinson’s disease.

鶹ý: October 2024 Issue of Neurosurgical Focus: Video: “Movement Disorders”
30-Sep-2024 9:05 AM EDT
October 2024 Issue of Neurosurgical Focus: Video: “Movement Disorders”
Journal of Neurosurgery

Announcement of contents of the October 2024 issue of Neurosurgical Focus: Video

鶹ý: Automatic Speech Recognition Learned to Understand People with Parkinson’s Disease — by Listening to Them
Released: 27-Sep-2024 11:05 AM EDT
Automatic Speech Recognition Learned to Understand People with Parkinson’s Disease — by Listening to Them
Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign

Listening to people with Parkinson’s disease made an automatic speech recognizer 30% more accurate, according to initial findings from the Speech Accessibility Project. Speech recordings used in the study are freely available to organizations looking to improve their voice recognition devices.

     


close
2.29388